MoonLake Immunotherapeutics (MLTX) News Today $10.66 +0.40 (+3.90%) Closing price 04:00 PM EasternExtended Trading$10.63 -0.03 (-0.28%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights2 hours ago | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTXOctober 13 at 1:50 PM | prnewswire.comChief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More SharesOctober 11 at 8:21 PM | finance.yahoo.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Time to Buy?October 11 at 12:59 PM | marketbeat.comMLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsOctober 11 at 9:31 AM | markets.businessinsider.comMLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics for Possible Securities Fraud ViolationsOctober 10 at 10:52 PM | theglobeandmail.comMLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsOctober 10 at 8:12 PM | prnewswire.comLifeSci Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)October 10 at 5:51 PM | theglobeandmail.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Should You Buy?October 10 at 5:26 PM | marketbeat.comSecurities Investigation: Levi & Korsinsky Investigates MoonLake Immunotherapeutics (MLTX) on Behalf of InvestorsOctober 10 at 12:50 PM | theglobeandmail.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Sell (D-) Rating from Weiss RatingsOctober 10 at 9:23 AM | marketbeat.comMLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost MoneyOctober 10 at 8:18 AM | globenewswire.comCFO Makes Bold Move with Major Stock Purchase in MoonLake ImmunotherapeuticsOctober 9, 2025 | tipranks.comMOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of StockholdersOctober 9, 2025 | globenewswire.comMoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens BermanOctober 9, 2025 | globenewswire.comCan Legal Pressures Reshape Confidence in MoonLake Immunotherapeutics’ (MLTX) R&D Pipeline?October 9, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTXOctober 8, 2025 | prnewswire.comMLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsOctober 8, 2025 | globenewswire.comMLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results -- Contact BFA LawOctober 8, 2025 | globenewswire.comResearch Analysts Issue Forecasts for MLTX FY2025 EarningsOctober 8, 2025 | americanbankingnews.comRosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTXOctober 7, 2025 | prnewswire.comMoonLake Immunotherapeutics price target lowered to $25 from $104 at OppenheimerOctober 7, 2025 | msn.comMOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the FirmOctober 7, 2025 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Trevi Therapeutics (TRVI)October 7, 2025 | theglobeandmail.comMoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTXOctober 6, 2025 | prnewswire.comMLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law FirmOctober 6, 2025 | prnewswire.comMLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 6, 2025 | globenewswire.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 9.9% - Should You Buy?October 6, 2025 | marketbeat.comMoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's InvestigationOctober 6, 2025 | globenewswire.comMLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics Investigated for Securities Fraud after 90% Stock Drop – Contact BFA LawOctober 6, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for MLTX FY2025 Earnings?October 6, 2025 | marketbeat.comMLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsOctober 5, 2025 | globenewswire.comMLTX INVESTIGATION NOTICE: BFA Law Notifies MoonLake Immunotherapeutics Investors of Pending Securities Fraud Investigation for Investors seeking RecoveryOctober 5, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal ScrutinyOctober 4, 2025 | finance.yahoo.comMLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost MoneyOctober 4, 2025 | globenewswire.comResearch Analysts Set Expectations for MLTX Q1 EarningsOctober 4, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Still a Buy?October 3, 2025 | marketbeat.comMLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 3, 2025 | globenewswire.comMoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens BermanOctober 3, 2025 | globenewswire.comMLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsOctober 3, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTXOctober 3, 2025 | prnewswire.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Cut to Neutral at HC WainwrightOctober 3, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for MLTX Q2 EarningsOctober 3, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Outlook for MLTX EarningsOctober 3, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (MLTX) Receives a Buy from Leerink PartnersOctober 2, 2025 | theglobeandmail.comMoonLake Immunotherapeutics (MLTX) was downgraded to a Hold Rating at JefferiesOctober 2, 2025 | theglobeandmail.comRosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTXOctober 2, 2025 | prnewswire.comHC Wainwright & Co. Downgrades MoonLake Immunotherapeutics (MLTX)October 2, 2025 | msn.comMOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces Investigation into MoonLake Immunotherapeutics on Behalf of MoonLake Stockholders and Encourages Investors to Contact the FirmOctober 2, 2025 | globenewswire.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Neutral" Rating at HC WainwrightOctober 2, 2025 | marketbeat.com Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.240.77▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼297▲MLTX Articles Average Week Get the Latest News and Ratings for MLTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for MoonLake Immunotherapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NTLA News Today OCUL News Today ANIP News Today VERA News Today TWST News Today DYN News Today APGE News Today COGT News Today TLRY News Today ABCL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
